GENB logo

GENBGenerate Biomedicines Inc

$13.13
$0.35
(2.74%)
Today
Updated: 01:58 PM EDT
EarningsAug 6
Mkt Cap$1.64B
Vol388,940.00
News
all
press releases
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
Key PointsHarbourVest initiated 1,722,210 shares of Generate Biomedicines last quarter; the estimated trade size was $21.03 million based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire SOMERVILLE, Mass., May 28, 2026 SOMERVILLE, Mass., May 28, 2026 /PRNewswire...
PR Newswire
News Placeholder
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire SOMERVILLE, Mass., May 7, 2026 SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials...
PR Newswire
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High - Should You Buy?
Generate Biomedicines (NASDAQ:GENB) Reaches New 52-Week High - Time to Buy...
MarketBeat
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Trading Up 8.1% - Should You Buy?
Generate Biomedicines (NASDAQ:GENB) Shares Up 8.1% - Still a Buy...
MarketBeat
News Placeholder
Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Rating of "Moderate Buy" by Analysts
Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings...
MarketBeat
News Placeholder
Research Analysts Set Expectations for GENB Q1 Earnings
Generate Biomedicines Inc (NASDAQ:GENB - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for Generate Biomedicines in a report issued on Monday, April 13th. HC...
MarketBeat
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Shares Up 7% - What's Next?
Generate Biomedicines (NASDAQ:GENB) Trading Up 7% - Time to Buy...
MarketBeat
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at HC Wainwright
HC Wainwright initiated coverage on Generate Biomedicines in a research note on Monday. They issued a "buy" rating and a $16.00 price objective on the stock...
MarketBeat
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Trading Down 6.9% - Time to Sell?
Generate Biomedicines (NASDAQ:GENB) Shares Down 6.9% - Time to Sell...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.